By Christian Moess Laursen
AstraZeneca said Wednesday that trial results showed that its Tagrisso drug in combination with chemotherapy demonstrated strong improvement for patients with lung cancer
The Anglo-Swedish pharmaceutical company said the FLAURA2 Phase 3 trial was for progression-free survival–the length of time a patient lives with a disease without it getting worse–for patients with epidermal growth factor receptor-mutated, non-small cell lung cancer.
For the moment, the overall survival data–the length of time from the start of diagnosis or treatment that the patient is still alive–were still immature and will be formally assessed at a subsequent analysis, AstraZeneca said.
“These significant FLAURA2 results show Tagrisso has the potential to offer patients in the first-line setting a new treatment option that can extend the time they live without their disease progressing,” Executive Vice President of the company’s Oncology R&D Susan Galbraith said.
Write to Christian Moess Laursen at christian.moess@wsj.com
Read the full article here
